このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Jianmin Pharmaceutical GroupLtd マネジメント

マネジメント基準チェック /24

Jianmin Pharmaceutical GroupLtd'sの CEO はJun Wangで、 Sep2022年に任命され、の在任期間は 1.75年です。は、会社の株式の0.23%を直接所有しており、その価値はCN¥ 21.47M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と1.8年です。

主要情報

Jun Wang

最高経営責任者

CN¥891.4k

報酬総額

CEO給与比率	n/a
CEO在任期間	1.8yrs
CEOの所有権	0.2%
経営陣の平均在職期間	1.8yrs
取締役会の平均在任期間	1.8yrs

経営陣の近況

Recent updates

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jun 30

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

May 21

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

Apr 26

CEO（最高経営責任者

Jun Wang (47 yo)

1.8yrs

在職期間

CN¥891,400

報酬

Mr. Jun Wang was Vice President of KPC Pharmaceuticals,Inc until September 08, 2020. He is Managing Director of Jianmin Pharmaceutical Group Co.,Ltd. He is Director and President of Jianmin Pharmaceutical...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jun Wang	President	1.8yrs	CN¥891.40k	0.23% CN¥ 17.5m
Chaoyang Cheng	Financial Director	1.8yrs	CN¥511.20k	0.056% CN¥ 4.3m
Zhenbo Hu	VP & Director	less than a year	CN¥210.40k	データなし
Jie Zhou	Secretary	1.8yrs	CN¥408.80k	0.024% CN¥ 1.9m
Xuejun Pei	Vice President	1.8yrs	CN¥540.00k	0.12% CN¥ 9.2m
Zhijun Huang	Vice President	1.8yrs	CN¥540.00k	0.11% CN¥ 8.2m

1.8yrs

平均在職期間

49yo

平均年齢

経験豊富な経営陣: 600976の経営陣は経験豊富とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Jun Wang	President	1.8yrs	CN¥891.40k	0.23% CN¥ 17.5m
Zhenbo Hu	VP & Director	less than a year	CN¥210.40k	データなし
Qin He	Chairman	1.8yrs	CN¥2.10m	0.27% CN¥ 20.8m
Qijing Xiao	Chairman of the Supervisory Board	1.8yrs	データなし	データなし
Yunpei Guo	Independent Director	1.8yrs	CN¥90.00k	データなし
Rong Pei	Director	1.8yrs	CN¥60.00k	データなし
Liang Xu	Director	1.8yrs	CN¥60.00k	データなし
Shuqu Li	Independent Director	1.8yrs	CN¥90.00k	データなし
Hu Jian	Supervisor	1.8yrs	データなし	データなし
Li Chen	Supervisor	1.8yrs	データなし	データなし
Jingqiu Tang	Supervisor	1.8yrs	データなし	データなし
Zhi Yang	Independent Director	1.8yrs	CN¥90.00k	データなし

1.8yrs

平均在職期間

53.5yo

平均年齢

経験豊富なボード: 600976の取締役会は経験豊富ではない ( 1.8年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Jianmin Pharmaceutical GroupLtd マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

No independent directors

Recent updates

We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024

We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease

We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings

First quarter 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.65 in 1Q 2023)

Jianmin Pharmaceutical Group Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024

Jianmin Pharmaceutical Group Co.,Ltd., Annual General Meeting, Apr 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Jianmin Pharmaceutical Group Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 16, 2024

Jianmin Pharmaceutical Group Co.,Ltd. to Report First Half, 2023 Results on Aug 16, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

No independent directors

Third quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.59 in 3Q 2021)

Investor sentiment improved over the past week

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

Second quarter 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.64 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.45 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.64 (vs CN¥0.25 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.60 in FY 2019)

Jianmin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥24.68

Third quarter earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

New 90-day high - CN¥25.64

First half earnings released

Jianmin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 13, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24